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Abstract
Apoptosis-inducing factor (AIF) plays a crucial role in caspase-independent programmed cell death by triggering chromatin
condensation and DNA fragmentation. Therefore, it might be involved in cell homeostasis and tumor development. In this
study, we report significant AIF downregulation in the majority of renal cell carcinomas (RCC). In a group of RCC specimens,
84% (43 out of 51) had AIF downregulation by immunohistochemistry stain. Additional 10 kidney tumors, including an
oxyphilic adenoma, also had significant AIF downregulation by Northern blot analysis. The mechanisms of the AIF
downregulation included both AIF deletion and its promoter methylation. Forced expression of AIF in RCC cell lines induced
massive apoptosis. Further analysis revealed that AIF interacted with STK3, a known regulator of apoptosis, and enhanced
its phosphorylation at Thr180. These results suggest that AIF downregulation is a common event in kidney tumor
development. AIF loss may lead to decreased STK3 activity, defective apoptosis and malignant transformation.
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Introduction
Renal cell carcinoma (RCC) accounts for approximately 90% of
all kidney malignancies with rising incidence over the last decades
[1,2]. Nephrectomy is effective in removing early tumors.
However, when metastasis occurs, RCC is very difficult to treat
and has poor prognosis. In spite of recent developments in
targeted therapy, which significantly extend median survival, most
patients still succumb to cancer.
Apoptosis-inducing factor (AIF) was initially identified as a
death effector involved in caspase-independent apoptosis pathway
[3–5]. Full length AIF is synthesized in cytoplasm as a precursor
(67 kDa). When transported into mitochondria, the precursor is
processed by cutting the first 34 amino acids and becomes a
62 kDa mature AIF (AIFmit) that acts as an NADH oxidase [6,7].
In normal cell, AIF anchors to the inner mitochondrial membrane
and plays a vital function in maintaining mitochondrial structure
and respiratory chain. In response to apoptotic stimuli, AIF is
cleaved by calpains or cathepsins to yield a 57 kDa truncated form
that translocates to the nucleus to induce DNA condensation and
large-scale fragmentation in the presence of endonuclease G
(EndoG) [8–11]. Recent studies on necroptosis, a regulated type of
necrosis, have revealed that AIF plays several roles in alkylating
DNA damage agent N-methyl-N9-nitro-N9-nitrosoguanidine-me-
diated necroptosis [12]. AIF is reported to interact with histone
H2AX and form a DNA-degrading complex with cyclophilin A
[13,14]. In addition to its role in cell death, AIF is also involved in
cell survival. For example, AIF-deficient cells have incomplete
complex I and are susceptible to peroxide-induced apoptosis [15].
AIF also participates in maintaining the transformed state of colon
cancer cells [16].
Serine/threonine-protein kinase 3 (STK3, also called MST2) is
a pro-apoptotic cytoplasmic kinase belonging to the Ste-20 kinase
family. STK3 and its family member STK4 (MST1) are the core
elements of mammalian Hippo pathway that controls cell
development, proliferation, apoptosis, and various stress responses.
In the Hippo signaling pathway, STK3 can be activated by
binding to the adaptor Salvador Homolog 1(WW45). Activated
STK3 can then further activate its downstream kinase, Large
Tumor Suppressor Kinase (LATS), which phosphorylates both
Yes-Associated Protein (YAP) and Tafazzin (TAZ). Phosphoryla-
tion allows YAP and TAZ to be retained by 14-3-3 protein in the
cytoplasm, so that they cannot translocate to nucleus to regulate
gene transcription [17,18]. STK3 is also involved in several pro-
apoptotic processes. Ras association domain-containing protein 1
(RASSF1A) induces apoptosis by both releasing STK3 from Raf1
binding and enhancing STK3 interaction with LATS1 [19]. In the
MST-FOXO signaling pathway that mediates oxidative stress-
induced neuronal death, STK3/STK4 (MST2/MST1) phosphor-
ylate forkhead box protein O3 (FOXO3) [20]. The phosphory-
lation of FOXO3 disrupts its interaction with 14-3-3 proteins and
promotes FOXO3 translocation to the nucleus. Overexpression of
STK3 or STK4 (MST1) induces a caspase-independent morpho-
logical change characteristic of apoptosis. These cells are also more
sensitive to death receptor-mediated apoptosis than their wild-type
counterparts [21]. STK4 activation can also induce H2B
phosphorylation and chromatin condensation via a caspase-
dependent pathway [22,23]. In addition, multiple apoptotic agents
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e100824Figure 1. Downregulation of AIF in kidney tumors. (A) A northern blot analysis of 19 types of tumors was performed with an AIF-specific cDNA
probe. Significant AIF downregulation was detected in various kidney tumors (from top to bottom: RCC, oxyphillic adenoma, RCC, RCC, transitional
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activation in cultured mammalian cells [24]. Although high levels
of STK3 have been observed in human kidney, its roles in kidney
has not been described thoroughly [25].
In this study, we show that AIF is significantly down regulated in
RCC and AIF interacts with STK3. Furthermore, overexpression
of AIF in RCC results in STK3 activation and cell death. It should
be noted that AIF is located on chromosome X. Interestingly,
kidney tumors are often more common in male (female to male
ratio is 1:1.6 for RCC) and male patients typically have higher
possibility of metastatic spread and worse prognosis, particularly in
clear cell renal cell carcinoma (CCRCC) [26,27]. These findings
indicate that genes on chromosome X play a role in RCC
development, and the function of AIF in tumorigenesis is related to
its regulation on STK3.
Materials and Methods
Tumor specimens
Renal cell carcinoma tissue specimens including 51 formalin-
fixed and paraffin embedded samples, and 37 liquid nitrogen-
frozen samples with the paired normal adjacent tissues were
obtained from the First Affiliated Hospital, Harbin Medical
University from 2005 to 2009. Clinicopathologic data are
summarized in Table S1. Tumor types and stages were assigned
according to UICC criteria. All the clinical samples were obtained
from patients with written informed consent. The usage of
patients’ samples was approved by the Medical Ethics and Human
Clinical Trial Committee of the First Affiliated Hospital, Harbin
Medical University.
Cell culture
Human Embryonic Kidney 293 cells (HEK293) were grown in
Dulbecco’s modified Eagle’s medium (Corning Cellgro, USA)
supplemented with 10% fetal bovine serum (FBS) (GIBCO, USA)
and 200 mM L-glutamine (Sigma, USA). RCC cell lines Caki-1
(HTB-46) and 786-O (CRL-1932) were grown in RPMI 1640
medium (Corning Cellgro, USA) with 10% FBS and 200 mM L-
glutamine. All cells were cultured at 37uC in humidified incubator
with 5% CO2.
Plasmid construction and transfection
Total RNA was extracted from HEK293 cell using TRIzol
reagent (Invitrogen, USA). First strand cDNA was synthesized
using cDNA Synthesis Kit (Thermo, USA). AIF transcript variant
1 and STK3 were amplified and cloned into pcDNA3.1 (Invitrogen,
USA), pGEX-6p-1 (GE Healthcare, USA) or pCMV-FLAG (pCMV-
HA was from Clontech, with HA tag replaced by FLAG).
Transient transfections were performed using Lipofectamine-
2000 reagent (Invitrogene, USA) according to manufacturer’s
protocol.
AIF Northern blot analysis
A tumor tissue array (BD Clontech Cancer Profiling Array II)
was hybridized with a p32-labeled AIF cDNA probe, detected by
exposing to an X-ray film. p32-labeled ATN cDNA probe was also
hybridized as control. Hybridization and washing conditions were
performed according to manufacturer’s protocol.
Immunohistochemistry and Western blot analysis
Tumor sections were heat-treated to retrieve antigen, blocked in
3% BSA in PBST for 30 min and incubated with AIF antibody
(Santa Cruz Biotech, sc-55519, USA; 1:200 dilution in PBST)
overnight at 4uC [28]. HRP-goat anti-mouse secondary antibody
(1:1000 dilution in PBS) (Santa Cruz, USA) was added for 1 h and
detected by diaminobenzidine (Sigma, USA). Cells were counter-
stained with hematoxylin. Antibody testing is showed on Fig. S1.
For western blot analysis, cryostat sliced frozen tissue were lysed
in RIPA buffer with PMSF and protease inhibitor cocktails
(Thermo, USA). Crude protein lysates were used for analysis. All
the western blot tests were repeated at least three times. Quantity
One software was used in the quantification of western blot data.
GST pull-down assay and immunoprecipitation
For GST pull-down assay and immunoprecipitation, cultured
cells were harvested using non-denaturing lysis buffer with PMSF
cell carcinoma, CCRCC, transitional cell carcinoma, RCC, epithelial nephroblastoma, and cancer of left kidney). Equal RNA loading was verified by
hybridization with actin. N, normal tissue; T, Tumor tissue. (B) Immunohistochemistry showed AIF downregulation in RCCs. AIF was expressed in
normal renal tubule (arrowhead) but not in glomeruli (arrow) (up left panel), and no AIF signals were seen in an RCC (up right panel). Assay of AIF
expression in a normal kidney with partial adjacent cancer tissue and paired RCC tissue from the same patient are shown on bottom panel. Strong
staining of AIF was observed in normal kidney part (lower left panel) compared to very weak staining in cancer part (lower right panel). (C) Western
blot analyses of 20 CCRCCs with paired normal tissues showed no expression of AIF or significant AIF downregulation in 17 CCRCCs. Only three cases
(#34, #37, #26) didn’t show AIF downregulation. N, normal tissue; C, cancer tissue.
doi:10.1371/journal.pone.0100824.g001
Table 1. AIF expression in clinical samples of kidney tumors.
AIF expression level
Feature n +,+++ 2,2/+*
Normal 37 37 (100%) 0 (0%)
RCC 51 8 (15.7%) 43 (84.3%)
CCRCC 45 7 (15.6%) 38 (84.4%)
Others ** 6 1 (16.7%) 5 (83.3%)
*+++ : .50% cells stained and brown in tissue; ++: 20–50% cells stained and snuff color in tissue; +: mild to moderate staining of 5–20% cells in tissue; 2 /+ : ,5% of
cells stained and faint in tissue; 2: negative, non-stained cells in tissue;
P value between Normal and Tumor group is less than 0.001.
**Others contain 4 papillary RCC, 1 renal oncocytoma and 1 chromophobe RCC.
doi:10.1371/journal.pone.0100824.t001
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were used: anti-AIF antibody (Abcam; ab1998), anti-STK3 and
phospho-STK3 antibodies (Cell Signaling; #3952 and #3681),
anti-V5 tag and anti-FLAG tag antibodies (Abcam; ab27671 and
ab45766), anti-Caspase-3 and anti-actin antibodies (Santa Cruz;
sc-56046 and sc-1616).
GST and GST-AIF plasmids were transformed into E. coli
BL21 (DE3) and cultured at 37uC until OD600 reached 1.0. At this
point, IPTG was added (final concentration of 0.25 mM) and cells
were then clutured at 16uC for 6 h. The GST or GST-AIF fusion
proteins were extracted with lysis buffer and sonicated on ice. After
centrifuge, the supernatant of E.coli lysates was immobilized onto
glutathione-sepharose 4B resin (GE, USA) at 4uC for 2 h. For the
GST pull-down assay, the immobilized GST or GST-fusion
proteins were incubated with cell lysates at 4uC for 2 h. After
being washed for six times, proteins remaining on the sepharose
beads were resuspended with SDS sample buffer, resolved with
SDS-PAGE and stained by Coomassie Brilliant Blue G-250. All
interested bands were analyzed by Mass-spectrometry.
For immunoprecipitation, pcDNA3.1-AIF-V5 or pCMV-Flag-
STK3 were transfected into Caki-1 cells separately. Cells were
harvested with lysis buffer 12 h later. After pre-clean, cell lysates
were incubated overnight with V5 or FLAG antibody. Immune
complex were precipitated by adding protein A beads (GE, USA)
and detected by western blot.
Figure 2. AIF deletion and promoter methylation in kidney tumors. (A) FISH analyses of 2 RCCs showed loss of AIF (red) as compared to a
control chromosome X centromere probe (green). (B) Bisulfite sequencing analyses of AIF promoter region in 4 paired male CCRCCs had aberrant
methylation patterns including CpA (green), CpT (red) and CpG (blue). Location of each methylation point is noted at the bottom. Height of columns
reflects the frequency detected in CCRCCs. (C) Bisulfite sequencing analyses of AIF promoter region in RCC cell line Caki-1. (D & E) Caki-1 cells were
treated with demethylation agent 5-aza-dC at 5 mM or vehicle DMSO for various periods of time; and western blot was performed with antibodies to
AIF and actin. AIF levels were quantitated by normalization to actin.
doi:10.1371/journal.pone.0100824.g002
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Dual-color FISH was performed as described [31]. BAC DNA
clone RP3-438D16 (BACPAC Resources Center, USA) contain-
ing the entire AIF genome sequence was labeled with rhodamine
using BioPrime DNA Labeling System (Life Technologies, USA).
Chromosome X centromeric probe (Metasystems, USA) was used
as a control probe. Hybridization signals were counted in 100
morphologically intact nuclei for each case using a Leica DMRB
fluorescence microscope equipped with a 1006 oil immersion
objective. AIF allelic reduction (or deletion) was scored if AIF
signals were less than the control centromere probe in a cell. The
cutoff value for an AIF deletion established from non-neoplastic
kidney tissue for this probe was 5%.
AIF promoter bisulfite-PCR and sequencing
Three pairs of overlapping bisulfite-specific PCR (BSP) primer
sets, covering the fragment from 2635 to +860, were designed
according to the instructions of Bisulfite Primer Seeker Program
(www.zymoresearch.com/tools/bisulfite-primer-seeker). Primer
sequences are showed in Table S2. DNA samples were treated
with EZ DNA Methylation-Gold Kit (Zymo Research Corp.,
USA) for bisulfite conversion. PCR were performed with the
corresponding primer sets 30 cycles each. PCR products were
cloned into pMD18-T Vector (Takara, Japan). Ten clones from
each case were selected randomly for sequencing using BigDye
Direct Cycle Sequencing Kit (Applied Biosystems, USA). Applied
Biosystems 3500 and 3500 Series Data Collection Software were
used for DNA sequencing and data analysis.
Apoptosis analysis
Cell apoptosis was assessed by Annexin V-FITC Apoptosis
Detection Kit I (BD Biosciences). Briefly, cells (1610
6/well) were
plated in six-well plates and cultured overnight. After transfection
with pcDNA3.1-AIF-V5, cell were collected at different time points
(from 8 h to 16 h), and stained with Annexin V-FITC/PI followed
by FACS analysis.
Statistics
The statistical significance of AIF expression difference between
RCC and normal kidney tissues was determined by Student’s T
test. A value of p,0.05 was considered statistically significant.
Results
AIF is down regulated in RCC
A northern blot analysis of 154 tumors and corresponding
normal tissues (BD Clontech Cancer Profiling Array II) showed
that, among 19 tissue types, AIF is expressed highest in normal
kidney. AIF downregulation was detected in various kidney tumors
including a benign renal oxyphilic adenoma, RCCs, and
transitional cell carcinomas (Fig. 1A). No significant AIF
downregulation was detected in the remaining 18 tumor types.
We studied AIF protein expression by immunohistochemistry on
51 cases of kidney tumors including 45 clear cell RCC (CCRCC),
4 papillary RCCs, a chromophobe RCC and a renal oncocytoma.
Among 51 tumors, 37 cases had matching normal kidney tissue
specimens. While all normal kidney had strong AIF signals in the
convoluted tubules (++ or +++), none or decreased AIF (2 or 2/+
Figure 3. Forced AIF expression induced apoptosis in RCC cells. (A) Caki-1 or (B) 786-O cells were transfected with pcDNA3.1-AIF or vector
only. Cells were harvested at various time points and apoptosis was evaluated by FCM with Annexin V-FITC/PI double stain kit. Apoptotic cell
percentage is shown in the line chart. AIF expression was analyzed by Western blot. Relative folds of AIF expression were noted on the upper part of
the panel. (C) Caki-1 cells were transfected with pDsRed (control) or pDsRed+pcDNA3.1-AIF (1:10). AIF was detected by immunofluorescence stain. Cells
with AIF overexpression underwent apoptosis (nuclear break down and nuclear localization of AIF).
doi:10.1371/journal.pone.0100824.g003
Figure 4. AIF interacted with STK3. (A) Immunorecipitation was performed in Caki-1 cells expressing pcDNA3.1-AIF-V5 or pCMV-flag-STK3;
Endogenous STK3 co-precipitated with AIF-V5, FLAG-STK3 was pulled down with endogenous AIF. (B) Caki-1 or 786-O cells transfected with
pcDNA3.1-AIF were harvested at various time points and western blots were performed with antibodies against AIF, phosphor-STK3, STK3, caspse-3
and actin. Relative folds are noted on each panel. AIF overexpression induced significant increase of STK3 phosphorylation at Thr180.
doi:10.1371/journal.pone.0100824.g004
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samples showed decreased AIF expression compared with the
normal ones (Fig. 1B; Table 1 and Table S3). In addition, no
significant associations between AIF expression and tumor
characteristics (size, metastasis, age and gender) were detected in
CCRCCs (Fisher’s exact test, p.0.05) (Table S4). Since CCRCC
is the most common type representing around 80% of all RCC in
most series [32,33], we focused on AIF expression in CCRCCs.
To confirm the immunohistochemistry findings, we randomly
chose 20 of these 45 CCRCC tumors for a western blot analysis,
significant AIF downregulation was detected in 17 out of 20 cases
(Fig. 1C). Overall, these findings show that AIF downregulation is
a common event in RCC, especially in CCRCC.
AIF genome DNA deletion and promoter methylation in
RCC
To detect potential AIF mutations, AIF was amplified by exon-
by-exon PCR in 37 pairs of RCC/normal tissues and PCR
products were analyzed by SSCP (PCR primer sets are showed in
Table S5). No significant AIF mutations were detected in these
tumors. We performed AIF FISH analysis using a BAC clone
containing the entire AIF genome sequence, and identified AIF
allelic reduction in 2 out of 11 tumors (Fig. 2A).
Since AIF genome deletion was not accountable for most RCCs
with AIF downregulation, we studied the methylation status of AIF
promoter region. A 1495 bp region (2635 to +860) covering
70 CpG dinucleotides was selected for methylation studies. To
circumvent the interference of hypermethylated loci on the
inactive X-chromosome in females, 4 pairs of male CCRCC
samples with downregulated AIF (no apparent AIF loss) and a
male RCC cell line Caki-1 were selected for AIF promoter
methylation studies. Bisulfite sequencing showed a complicated
DNA methylation profiling (Fig. 2B). Multiple DNA methylation
sites, including non-CpG methylation, were detected in all 4 tumor
samples. Most common methylation sites in RCC were, in
descending order: 96 (CpT), 149 (CpT), 2316 (CpG), 2309
(CpT), +303 (CpG), and +306 (CpT) (Fig. S2). In addition, we
detected a unique constant CpT methylation at +561 in Caki-1
cell as shown in Figure 2C.
To study whether AIF promoter methylation affects AIF
expression, Caki-1 cells were treated with a DNA demethylating
agent 5-aza-29-deoxycytidine (5-aza-dC) at 5 mM for 24 h, which
led to almost three-fold increase of AIF as compared to the
vehicle-treated controls (Fig. 2D and 2E). Taken together, these
results demonstrate that aberrant AIF promoter methylation is a
common event in RCC that may play a major role in AIF
downregulation in these tumors.
AIF overexpression induces apoptosis in RCC cells
To study whether forced expression of AIF affects tumor cell
growth, pcDNA3.1-AIF was transiently transfected into 2 RCC cell
lines, Caki-1 and 786-O. As shown in Figure 3A and 3B, AIF
overexpression induced massive apoptosis in both Caki-1 and 786-
O cells. Indeed, most transfected cells were dead and detached
from culture flasks within 24 h after transfection. As determined
by immunofluorescence stain, Caki-1 cells overexpressing
pcDNA3.1-AIF had AIF signals in nuclei, consistent with its role
in apoptosis (Fig. 3C).
AIF interacts with STK3 and induces STK3
phosphorylation in RCC cell line
To study the mechanisms of AIF-induced apoptosis in RCC, we
performed a GST-AIF pull down assay using Caki-1 cell lysates.
Pull down products were separated in a SDS-PAGE gel and
proteins were identified by mass spectrometry. One of the AIF-
interacting proteins was STK3 (Fig. S3). To confirm this result,
pcDNA3.1-AIF-V5 was expressed in Caki-1 cells, and immunopre-
cipitation was performed with anti-V5 antibody. Endogenous
STK3 was detected by western blot in the co-precipitation of AIF-
V5. A similar study of Caki-1 cells overexpressing FLAG-tagged
STK3 showed co-precipitation of STK3-FLAG with endogenous
AIF (Fig. 4A).
To study whether AIF expression affects STK3 activation, Caki-
1 and 786-O cells were transfected with pcDNA3.1-AIF construct.
AIF expression increased from 8 h to 14 h after transfection. As
AIF increased, a significant increment of STK3 phosphorylation
at Thr180 was detected, while the total STK3 did not change. No
significant caspase-3 activation was observed during these time
points (Fig. 4B).
Discussion
AIF was initially identified as a candidate tumor suppressor
because of its role in apoptosis. Upon an apoptotic signal, AIF
translocates from mitochondria to nucleus where it triggers
caspase-independent programmed cell death. Paradoxically, AIF
also plays a role in cell survival. It has been reported that AIF is
required to maintain the mitochondrial respiratory complex I.
Moreover, AIF is a free radical scavenger that prevents apoptosis
induced by reactive oxygen species [15,34]. In fact, the role of AIF
on cell death may be cell type-specific. For example, AIF gene
silencing protects renal tubular epithelial cells against cisplatin-
induced cell death [35]. However, AIF deficient human colon
carcinoma cells are more sensitive to peroxide- and drug-induced
apoptosis than the wild type counterparts [16]. AIF is predom-
inantly overexpressed in several tumors including colon and
squamous cell carcinomas [36,37]. In this study, we reported that
AIF expression was considerably higher in normal kidney as
compared to the remaining 18 tissue types studied. Furthermore,
significant AIF downregulation was detected in most kidney
tumors. These studies suggest a tissue-specific role of AIF in
tumorigenesis. AIF downregulation was also detected in a case of
adenoma, which indicates that AIF downregulation is an early
event in kidney tumor development. Our studies show that both
genomic deletion and promoter methylation cause AIF downreg-
ulation in RCC, although intragenic mutations were not
identified.
The profiling of DNA methylation in AIF promoter region
using bisulfite sequencing showed a complex pattern including
frequent methylcytosines in non-CpG sequences in RCC.
Furthermore, Caki-1 cells had a CpT methylation, and demeth-
ylation by 5-aza-dC enhanced AIF expression significantly.
Although the functional significance of non-CpG methylation is
not completely understood, increasing data have implied the
correlations between non-CpG methylation and tissue-specific
gene expression. For example, non-CpG methylation is reported
to be more prevalent in wild-type murine ES Cells than in tissues
[38], and studies of murine NF1 gene have revealed non-CpG
methylation in the oocyte and the maternally derived allele of the
2-cell embryo [39]. Recently, cytosine hypermethylation was
detected in peroxisome proliferator-activated receptor c coacti-
vator-1 a (PGC-1a) promoter region in diabetic specimens, and the
majority of the methylated cytosines were non-CpG methylation.
It has also been reported that human myotubes treated with tumor
necrosis factor-a (TNF-a) have acute increase of non-CpG
methylation level in PGC-1a promoter [40]. These findings
AIF in Renal Cell Carcinoma
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function in cells.
AIF induces DNA fragmentation and chromatin condensation
when entering the nucleus. However, the exact mechanisms are
not completely understood. It is well accepted that AIF does not
possess nuclease activity, and the DNA fragmentation induced by
AIF depends on its DNA binding capability. In an in vitro cell-free
system, AIF alone is capable of inducing chromatin condensation
and DNA loss in the isolated nuclei [41,42]. However, AIF has no
effect on preheated nuclei. This evidence suggests that other
nuclear factors are involved in AIF-induced chromatin condensa-
tion [43]. Three nuclear proteins have been reported to be
associated with AIF: Endonuclease G, Cyclophilin A, and H2AX.
H2AX is a major component of chromatin and plays a role in
assembling DNA repair complex when DNA damage occurs. The
interaction between AIF and H2AX is believed to play a role in
caspase-independent DNA fragmentation [13]. AIF binds to
H2AX only when its ser139 is phosphorylated. Interestingly,
STK4, a STK3 family member, is capable of phosphorylating
ser139 of H2AX [44]. Our study showed that AIF binds to STK3,
leading to increasing STK3 activity. We are currently studying the
possibility that AIF-induced STK3 activation phosphorylates
H2AX in kidney cells that, in return, binds to AIF to induce
apoptosis.
Kidney cancer is one of the most common cancers, and several
types of kidney tumors are more common in male. For example,
male-to-female ratios for CCRCC, Bellini duct carcinoma and
medullary carcinoma are approximately 2:1. Male patients also
have higher possibility of metastatic spread and worse prognosis in
CCRCC [26]. Interestingly, AIF is located on chromosome X.
Whether AIF is capable of escaping chromosome X inaction and
whether leaking AIF expression contributes to protection from
malignant transformation in female patients are probably worth
further evaluation.
In summary, our finding that AIF is frequently downregulated
in RCC suggests that loss of AIF may be involed in RCC
development. The interaction between AIF and STK3 also reveals
a novel role of AIF in regulating programmed cell death.
Targeting the AIF signaling pathway therefore may be a viable
option for the treatment of RCC patients.
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